NCT05280379Completed
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma
Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone marrow myeloid progenitor cells. Furthermore, treatment of these cells by nanoparticles or other agents that induce a program of 'trained immunity' may be a novel way to re-educate myeloid cells and their bone marrow progenitors in thyroid carcinoma patients. Lastly, the investigators expect that this approach could be effective also in other cancers of which colon carcinoma is here proposed as an additional model. The investigators hypothesize that by exposing myeloid cells or their progenitors to various agents that induce trained immunity (e.g. high-density-lipoprotein-methylene diphosphonate nanoparticles, recombinant and synthetic cytokines), these immune cells will undergo functional reprogramming to induce a tumor-suppressive phenotype. In the future, this could be explored as a novel immunotherapy for tumors that are refractory to conventional treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 33 (actual)
- First submitted
- 24 Feb 2022
- Start date
- 19 Sept 2022
- Primary completion date
- 1 May 2025
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Thyroid cancer, Colorectal cancer
- NCT number
- NCT05280379
What you commit to
- Study type: Observational
- Participants enrolled: 33
- From 19 Sept 2022 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Using medication interfering with the immune system
- Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor
Other illness
- Known inflammation or infectious disease or an immunosuppressive status
- Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas)
- Serious psychiatric pathology
Lab values
- Reduced platelets counts or other conditions associated with an increased risk of bleeding
Other
- Mentally incompetent
- Pregnant or breastfeeding
- A self-reported alcohol consumption of \>21 units per week
Who the study is looking for
- At least 18 years old and mentally competent
- Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve
- Planned to receive conventional treatment for the malignancy by surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.